Together, these findings provide impetus for the development of anti-tau antibodies as immunotherapeutics for AD based on the hypothesis that antibody binding to extracellular tau will prevent spread of pathological tau aggregates throughout the brain. Here, MAPT is linked to Alzheimer disease.